Development and commercialisation of a novel needle tract sealant system for pneumothorax prevention during lung biopsybroad
Selio System · Horizon Europe grant · 2022-10-01–2024-09-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
Every 30sec someone somewhere globally dies of lung cancer. EU records ~320,000 pa new lung cancer cases. Early lung cancer diagnosis can save lives through timely/efficient interventions. CT guided lung biopsy is the gold standard for lung cancer screening. However, it comes with 62% inherent risk of life-threatening complication pneumothorax (PTX)- a complete or partial lung collapse. PTX sufferers require further radiological scans, needle aspiration, chest tube insertion or surgery- requiring additional hospital stay & ~€15k cost-of-care. Currently no method or device prevents PTX during the percutaneous needle access of lung.Our patented Selio System will be world’s first system specifically designed to prevent PTX occurring before biopsy even takes place. Used by an interventional radiologist before lung biopsy procedure in a 2 min ‘add-on’ to the current standard of care, Selio System pre-seals the needle tract in tissue, thereby preventing air & blood leak from those organs
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| SELIO MEDICAL LIMITED | IE | coordinator | €2,499,999 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.